Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study

Jian-Xu Li1†, Wen-Xiang Deng1†, Shi-Ting Huang1, Xiao-Feng Lin1, Mei-Ying Long2, Jie Zhang3, Ting-Shi Su1, Li-Qing Li1, Ya-Dan Pang1, Chun-Feng Liang1, Hong-Mei Zhou1, Hai-Yan Lu1, Shi-Xiong Liang1 and Bang-De Xiang3*

Abstract

Background: The combination of transcatheter arterial chemoembolization (TACE) plus sorafenib prolonged progression-free survival (PFS) and overall survival (OS) than sorafenib or TACE monotherapy for patients with hepatocellular carcinoma (HCC). This study assessed the efficacy and safety of radiotherapy (RT) plus monoclonal antibody against programmed cell death 1 (anti-PD1) versus TACE plus sorafenib for patients with advanced HCC.

Methods: Patients with advanced HCC who treated with RT plus anti-PD1 and TACE plus sorafenib were enrolled. Objective response rate (ORR), PFS, disease control rate (DCR) and OS were calculated to assess the antitumor response and the treatment-related adverse events to the safety.

Results: Between January 2018 to March 2021, 37 patients underwent RT plus anti-PD1 and 41 patients underwent TACE plus sorafenib. The baseline characteristics between the two groups were comparable. The ORR and DCR were significantly higher in the RT+PD1 group than the TACE plus sorafenib group according to RECIST 1.1 (54.05% vs. 12.20%, \( P < 0.001 \); 70.27% vs. 46.37%, \( P = 0.041 \); respectively) and according to mRECIST (56.76% vs. 31.71%, \( P = 0.039 \); 70.27% vs. 46.37%, \( P = 0.041 \); respectively). RT plus anti-PD1 provided significantly better PFS (HR, 0.51; 95% CI 0.30–0.86; \( P = 0.017 \)) than TACE plus sorafenib. Moreover, patients with RT plus anti-PD1 had significantly higher 3-, 6-, and 9-month OS rates than those with TACE plus sorafenib (97.3% vs. 92.30%, \( P < 0.001 \); 91.89% vs. 68.60%, \( P < 0.001 \); 75.5% vs. 60.60%, \( P < 0.001 \); respectively). The median OS was more favorable 17.4 months for the RT + PD1 group and 11.9 months for the TACE plus sorafenib group. No treatment-related death was observed. Grade 3 or more treatment-related adverse events (TRAEs) occurred significantly less in patients in the RT + PD1 group than the TACE plus sorafenib group (29.7% vs. 75.6%, \( P < 0.001 \)), and all TRAEs were manageable.

Conclusions: In this real-world study, RT plus anti-PD1 showed significantly promising efficacy and manageable safety than TACE plus sorafenib in patients with advanced HCC. Toxicities were manageable, with no unexpected safety signals. The study provides evidence on a new therapeutic method in the treatment of advanced HCC.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Keywords: Hepatocellular carcinoma, Anti-PD1, Radiotherapy, Overall survival, Transcatheter arterial chemoembolization, Sorafenib

Background
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, which is the 6th most common cancer worldwide and the 3rd leading cause of cancer-related death [1]. Most patients are found at an advanced stage having a poor prognosis [2, 3]. TACE, RT and sorafenib are recommended as standard treatments for the patients with advanced HCC by The National Comprehensive Cancer Network (NCCN) guideline [4]. The combination of TACE with sorafenib is proved to be a well-tolerated and feasible treatment for patients with HCC [5, 6]. The combination of TACE and sorafenib prolonged progression-free and overall survival times than sorafenib or TACE monotherapy, and was indicated to be a promising treatment in patients with unresectable HCC [7–9].

With the rapid improvement of RT technology and equipment, the curative effect of RT for HCC has been significantly improved in recent years. Hypofractionated RT has also been shown to be effective in patients with HCC through excellent local control, downstaging, conversion from unresectable to resectable status, and treatments of unresectable HCC with vessel invasion or multiple intrahepatic metastases [10–12].

Recently, the IMbrave trial showed atezolizumab combined with bevacizumab achieved better OS and PFS than sorafenib, but the combination is expensive and the rate of grade 3 or more TRAEs was high with a high risk of grade 5 events [13]. Thus, new therapeutic strategies for advanced HCC are necessarily needed. The anti-PD1 has emerged to play a promising role in the treatment of advanced HCC [14]. RT can undergo a so-called immunogenic death inducing in situ vaccination and render the tumor microenvironment conducive to effector T-cell 4 recruitment and function to produce a synergistic anti-tumor immunity with anti-PD1 for durable disease control [15]. Early clinical trials combining RT with anti-PD1 showed clinical activity in several cancers including non-small cell lung cancer [16], malignant pigmented tumor [17], and esophageal squamous cell carcinoma [18]. A case report including 5 cases showed the impressive tumor control in patients with advanced HCC treated by the combination of RT and anti-PD1 [19].

To the best of our knowledge, there has been rare study to directly compare the efficacy and safety of anti-PD1 plus RT versus other strategies in the treatment of advanced HCC. Therefore, we performed this real-world study to evaluate the efficacy and safety of anti-PD1 plus RT versus TACE plus sorafenib in the treatment of advanced HCC, and seek a new approach for the treatment of advanced HCC.

Methods
Study design and patients
This is a retrospective real-world study that was conducted at Guangxi Medical University Cancer Hospital, Nanning, China. Consecutive patients were identified via the electronic medical records from January 2018 to March 2021. Of these patients, 99 patients with advanced HCC were screened and 78 patients were included based on the following chief eligibility criteria: (a) patients with advanced HCC not fit for radical cures such as hepatic resection or local ablation and Barcelona Clinic Liver Cancer (BCLC) B or C stage, (b) diagnosed according to histopathology, the European Association for the Study of the Liver (EASL) criteria [20] or American Association for the Study of Liver Diseases (AASLD) [21], (c) received RT plus at least one cycle synchronous, or sequential anti-PD1 or TACE plus synchronous or sequential oral sorafenib, (d) had at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [22] and an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, (e) aged between 18 and 70 years, (f) had Child–Pugh class A or B liver function, (g) an observation period of ≥ 1 months. The key exclusion criteria were patients combined intrahepatic cholangiocarcinoma, with incomplete medical information or lost to follow-up, treatment duration of sorafenib less than 1 month. A total of 78 patients were enrolled in this study with 37 in the RT+PD1 group and 41 in the TACE+sorafinib group.

The study was conducted with approval from the institutional ethics committee of Guangxi Medical University Tumor Hospital. The patient’s informed consent was obtained from all participants.

Anti-PD1 therapy
In the RT+PD1 group, anti-PD1 included pembrolizumab (Merck Sharp & Dohme Co., Inc.), camrelizumab (Jiangsu HengRui Medicine Co., Ltd.), toripalimab (Shanghai Junshi Biosciences Co., Ltd), tislelizumab (Beigene), and sintilimab [Innovent Biologics (Suzhou) Co., Ltd.]. Dose, method of injection and duration of anti-PD1 were according to the manufacturers instructions. The anti-PD1 were recommended to be used continually every 2 or 3 weeks until disease progression, or intolerable toxicity.
Hypofractionated intensity modulated radiotherapy
All patients treated with RT + PD1 underwent enhanced CT scan at 2.5–5 mm slice thickness for hypofractionated intensity modulated radiotherapy (hypo-IMRT) planning. Gross tumor volume (GTV) was defined as tumor focus that was visualized on contrast imaging. The clinical target volume (CTV) was defined as GTV plus a margin of 4–5 mm as described before [23]. The target volumes and organs at risk (OARs) were contour in the MIM 6.8 system (MIM, USA). Whenever conditions permitted, CT-positron emission tomography (PET-CT) fusion and CT-magnetic resonance imaging (MRI) fusion were performed. For patients with multiple metastases, 1–5 lesions were chosen for hypo-IMRT at the discretion of the radiation oncologists. The planned target volume (PTV) was defined as GTV or CTV plus asymmetrical dilation of 1 cm in craniocaudal direction and 5 mm in axial direction to set uncertainty and respiratory movement. The hypo-IMRT plans were designed using the Monaco treatment planning system (TPS) (version 5.1) or Pinnacle 3 system (Philips, Netherlands), and performed by volumetric-modulated arc therapy (VMAT) or intensity modulated radiotherapy (IMRT). The final median radiation dose delivered was 40 Gy (range, 30–60 Gy), with fraction of 4 Gy (range, 2.5–5). The most commonly used fractionations with percentage of lesions were 10 × 4 Gy; 20 × 3 Gy; 10 × 5 Gy; 10 × 3 Gy; 20 × 2.5 Gy. The RT was delivered daily over five fractions per week, using a 6 MV X-ray linear accelerator (EL-KTA Versa-HD). Cone-beam computed tomographic (CBCT) images were used to correct the positions.

Sorafenib therapy
In the TACE + sorafenib group, patients treated with sorafenib were prescribed with two tablets of sorafenib (200 mg tablet) twice daily (800 mg/day). If unacceptable treatment-related toxicity or disease progression occurs, dose reduction and treatment termination are allowed.

Transarterial chemoembolization
TACE was performed as described before [24]. Briefly, all patients in the TACE + sorafenib group underwent selective arteriography of the hepatic artery to locate the tumors and the percutaneous femoral artery was punctured using the Seldinger technique. The combination of local chemotherapy drug solution (cisplatin 80 mg/m² or pirarubicin 60–80 mg) and drug carriers (lipiodol or ethiodized poppy seed oil 5–15 mL) was introduced into the tumor. And blank CalliSpheres R microspheres was used to embolize the feeding artery of tumors Complete embolization of the tumor supplying artery with no tumor staining observed by angiography at the end of procedure was defined as a technical success. TACE was performed 1–2 months before or after sorafenib and repeated one to six times (median, 3) at 3–6-week intervals if the patient could tolerate and consent of further treatment.

Evaluation of efficacy and safety
The on-study date was defined as the day of acceptance of informed consent of sorafenib or hypo-IMRT planning. All TRAEs were recorded from on-study date until 30 days after last anti-PD1 injection or sorafenib, last follow-up as appropriate according to the Common Terminology Criteria for Adverse Events of the National Cancer Institute v5.0 (CTCAE 5.0). To evaluate tumour responses, RECIST 1.1 and modified Response Evaluation Criteria in Solid Tumors (mRECIST) [25] were used, respectively. The OS was defined as the on-study date to death from any cause. PFS was defined as the on-study date until disease progression or death. The ORR was defined as the proportion of patients with complete response (CR) or partial response (PR). Disease control was defined as the sum rate of CR+PR+stable disease (SD). All patients received follow-up visits every month for progression and survival status.

Statistical analysis
The data of all patients was collected through electronic medical records and enter the data into Research Electronic Data Capture (REDCap) [26]. Through the normal distribution test by visualization on a histogram and with Kolmogorov–Smirnov tests, the continuous variables conforming to the normal distribution were expressed as the mean ± standard deviation and visualized on a histogram and with Kolmogorov–Smirnov tests. The categorical variables were expressed as number and percentage. The t-test was used for the continuous variables conforming to normal distributions, and the Pearson's chi-square tests was used for categorical variables. OS and PFS were calculated and median OS and PFS were estimated for both groups by using Kaplan–Meier methods with the values compared using the Breslow generalized Wilcoxon test [27]. HR and CI were estimated using univariate Cox proportional risk model, and statistical analysis and forest mapping were performed using R 4.0.5 for the subgroups. All statistical tests were two tailed. IBM SPSS software (ver. 26.0 SPSS Inc., Chicago, IL, USA) was used for the statistical analysis unless otherwise indicated.

Results
Patients
Of the 78 patients with advanced HCC enrolled, 37 (47.4%) were in the RT + PD1 group and 41 (52.6%) were in the TACE + sorafenib group (Fig. 1). In the RT + PD1 group, there were 35 patients received PD1 inhibition
during RT, and 2 patients 1 month after the last RT fraction. The baseline characteristics of these patients were summarized and comparable between the two groups (Table 1). There were no significant differences in the distribution of gender, age, bodyweight, chronic hepatitis B/C virus infection, liver cirrhosis, alpha fetoprotein, albumin–bilirubin (ALBI) grade, maximum tumor diameter, macrovascular invasion, BCLC stage, hemoglobin, platelet count, white blood cell, and prior therapy between the two groups (Table 1). Patients with extrahepatic metastasis were more prevalent in the RT + PD1 group than in the TACE + sorafenib group (59.5% vs. 35.7%, respectively, \( P = 0.044 \)), while Albumin (< 35 g/L) were more common in the TACE plus sorafenib group than in the TACE plus RT group (76.2% vs. 46.0%, respectively; \( P = 0.010 \)).

In the RT + PD1 group, patients received median 5 (1–20) cycles anti-PD1 including 32 patients with camrelizumab (SHR-1210, Jiangsu HengRui Medicine Co., Ltd.) [28], 3 with sintilimab [IBI308, Innovent Biologics (Suzhou) Co. Ltd.] [29], 2 with tislelizumab (BGB-A317, BeiGene) [30]. All patients with much more lesions than hypo-IMRT targets received hypo-IMRT median dose 40 Gy (range 30–60 Gy) with median 4 Gy per fractions (range 2.5–5 Gy per fractions). The median duration of sorafenib therapy was 6.5 (range 1–20) months and the median number of TACE sessions was 2 (range 1–6) in the TACE + sorafenib group.

At data cutoff, 14 (37.8%) patients had received subsequent therapy including 1 received TACE plus hepatectomy, 2 received regorafenib, 2 received sorafenib, 2 received lenvatinib, 3 received TACE, and 4 received apatinib in the RT + PD1 group after disease progression. As to the TACE + sorafenib group, 16 (39.0%) patients had received subsequent therapy including one received radiofrequency ablation plus anti-PD1, 1 received hepatectomy plus anti-PD1, 1 received lenvatinib, 1 received lenvatinib plus anti-PD1, 1 received apatinib, 1 received regorafenib plus anti-PD1, 2 received hepatectomy, and 10 received anti-PD1.

**Radiologic response after treatment**

The median follow-up of the patients in the RT + PD1 group was 13.4 months (95% CI 12.1–14.6), and in the TACE plus sorafenib group was 16.6 months (95% CI 14.9–18.3), \( P = 0.034 \). The tumor responses are presented in Table 2. The PR rate, ORR and DCR were significantly higher in the RT + PD1 group than the TACE plus sorafenib group according to RECIST 1.1 (54.05% vs. 12.20%, \( P < 0.001 \); 54.05% vs. 12.20%,...
and according to mRECIST (56.76% vs. 31.71%, \(P = 0.039\); 54.05% vs. 12.20%, \(P < 0.001\); 70.27% vs. 46.34%, \(P = 0.041\); respectively). Best percent change from baseline in sum of longest diameters for target lesions per patient in the two groups is shown in the waterfall plot (Fig. 2), where Fig. A, B, C, and D represent the results in the RT + PD1 group based on RECIST 1.1, the TACE plus sorafenib group based on RECIST 1.1, the RT + PD1 group based on mRECIST, and the TACE plus sorafenib group based on mRECIST, respectively.

**Progression-free survival analysis**

Progression of the disease was observed in 37 of the patients (47.4%) who underwent RT + PD1 and 41 of the patients who underwent TACE plus sorafenib group (52.8%) during follow-up. Patients in the PD1 + RT group had significant better PFS compared with those in the TACE + sorafenib group (5.86 vs. 3.70 months; HR, 0.51; 95% CI 0.30–0.86; \(P = 0.017\); Table 2 and Fig. 3). The median PFS in the PD1 + RT group had significant longer than TACE + sorafenib group across subgroups based on age \(\geq 53\), infection of hepatitis B (HBV), the maximum tumor diameter < 10 cm, MVI, without extrahepatic metastasis, BCLC stage C, no prior TACE, prior hepatectomy, and no prior systemic therapy (\(P = 0.01\), 0.04, 0.031, 0.024, 0.049, 0.0067, 0.044, 0.024 and 0.016; respectively, Fig. 4A). The effect of the two groups on median PFS was consistent across subgroups based on other baseline characteristics (Fig. 4A).

**Overall survival analysis**

Among the 37 patients in the RT + PD1 group, 18 are still alive, 18 have died, and 1 is lost to follow-up by the end of this study. Among the 41 patients who received TACE plus sorafenib, 13 are still alive, 25 have died, and 3 are lost to follow-up. The 3-, 6-, and 9-month OS rates were

---

**Table 1** Patient baseline demographic and clinical characteristics

| Variables                              | RT + PD1, \(N = 37\) (%) | TACE + Sorafenib, \(N = 41\) (%) | \(P\) value |
|----------------------------------------|---------------------------|---------------------------------|-------------|
| Gender, male                           | 35(94.60%)                | 37(90.24%)                      | 0.678       |
| Age, year                              | 54.16 ± 10.68             | 51.71 ± 9.571                   | 0.288       |
| Bodyweight, kg                         | 63.58 ± 9.96              | 65.06 ± 10.84                   | 0.534       |
| Hepatitis B, present                   | 31(83.78%)                | 30(73.17%)                      | 0.286       |
| Hepatitis C, present                   | 1(2.70%)                  | 5(12.2%)                        | 0.204       |
| Liver cirrhosis, present               | 17(45.95%)                | 26(63.41%)                      | 0.171       |
| Alpha fetoprotein, \(\geq 400\) ng/ml  | 18(48.65%)                | 18(43.90%)                      | 0.820       |
| ALB grade, ≤ 2                         | 36 (97.3%)                | 38 (93.7%)                      | 0.617       |
| Blood bilirubin, \(> 21\) umol/L       | 9(24.32%)                 | 14(34.15%)                      | 0.457       |
| Albumin, < 35 g/L                      | 17(45.95%)                | 31(75.61%)                      | 0.010       |
| Hemoglobin, < 131 g/L                  | 22(59.46%)                | 19(46.34%)                      | 0.266       |
| Platelet count, \(< 100*10^9/L\)      | 7(18.92%)                 | 6(14.63%)                       | 0.763       |
| White blood cell, \(< 3.97*10^9/L\)   | 7(18.92%)                 | 4(9.76%)                        | 0.333       |
| Maximum tumor diameter, cm             | 7.30(4.75–8.65)           | 6.20(4.15–10.80)                | 0.860       |
| Maximum tumor diameter, \(\geq 10\) cm| 8(21.62%)                 | 13(31.71%)                      | 0.444       |
| Macrovascular invasion, present        | 16(43.24%)                | 24(58.54%)                      | 0.257       |
| Extrahepatic metastasis, present       | 22(59.46%)                | 14(34.15%)                      | 0.040       |
| BCLC stage                             |                           |                                 | 0.147       |
| B                                       | 4(10.81%)                 | 10(24.39%)                      | 0.619       |
| C                                       | 33(89.19%)                | 31(75.61%)                      | 1.000       |
| Prior therapy                          |                           |                                 |             |
| TACE, present                          | 11(29.73%)                | 10(24.39%)                      |             |
| Hepatectomy, present                   | 16(43.24%)                | 14(34.15%)                      |             |
| Systemic therapy, present              | 6(16.22%)                 | 6(14.63%)                       |             |

Data are mean ± standard deviation, median (IQR) or N (%)

RT Radiotherapy; PD1 The monoclonal antibody against programmed cell death 1; TACE Transcatheter arterial chemoembolization; ALB Albumin–bilirubin; BCLC Barcelona Clinic Liver Cancer

\(P < 0.001; 70.27\% vs. 46.34\%, \(P = 0.041\); respectively)
Table 2  Summary of efficacy outcomes

| Variables                                      | RT + PD1, N = 37 (%) | TACE + Sorafenib, N = 41 (%) | P value |
|------------------------------------------------|-----------------------|------------------------------|---------|
| According to RECIST 1.1                         |                       |                              |         |
| Confirmed objective response                    | 20 (54.05%)           | 5(12.20%)                    | <0.001  |
| Time to response, months, (IQR)                | 1.80(1.57–2.00)       | 2.87(1.407–6.86)             | 0.467   |
| Disease control                                 | 26(70.27%)            | 19(46.34%)                   | 0.041   |
| Best overall response                           |                       |                              |         |
| CR                                             | 20 (54.05%)           | 5(12.20%)                    | <0.001  |
| PR                                             | 6(16.22%)             | 14(34.15%)                   | 0.118   |
| SD                                             | 11(29.73%)            | 22(53.66%)                   | 0.041   |
| Progression-free survival, months, median, (95% CI) | 5.86(3.19–8.53)     | 3.70(2.60–4.80)              | 0.017   |
| According to mRECIST                            |                       |                              |         |
| Confirmed objective response                    | 21(56.76%)            | 13(31.71%)                   | 0.039   |
| Time to response, months, (IQR)                | 1.85(1.60–2.98)       | 1.47(0.80–2.60)              | 0.061   |
| Disease control                                 | 26(70.27%)            | 19(46.34%)                   | 0.041   |
| Best overall response                           |                       |                              |         |
| CR                                             | 2(2.70%)              | 2.44%                        | 1.000   |
| PR                                             | 20 (54.05%)           | 12(29.27%)                   | 0.038   |
| SD                                             | 5(13.51%)             | 6(14.63%)                    | 0.774   |
| PD                                             | 11(29.73%)            | 22(53.66%)                   | 0.041   |
| Progression-free survival, months, median, (95% CI) | 5.86(3.19–8.53)     | 3.70(2.60–4.80)              | 0.019   |
| Overall survival                                |                       |                              |         |
| 3-month, %                                      | 97.30%                | 92.30%                       | <0.001  |
| 6-month, %                                      | 91.90%                | 68.60%                       | <0.001  |
| 9-month, %                                      | 75.50%                | 60.60%                       | <0.001  |
| 12-month, %                                     | 52.20%                | 47.5%                        | 0.061   |
| Overall survival, months, median, (95% CI)     | 17.40 (8.69–26.11)    | 11.90 (6.35–17.45)           | 0.146   |

Data are N (%; 95% CI), unless indicated

RT Radiotherapy; PD1 The monoclonal antibody against programmed cell death 1; TACE Transcatheter arterial chemoembolization; RECIST 1.1 Response Evaluation Criteria in Solid Tumors 1.1; mRECIST Modified Response Evaluation Criteria in Solid Tumors; CR Complete response; PR Partial response; SD Stable disease; PD Progressive disease

significant better in the RT + PD1 group than that in the TACE plus sorafenib (97.3% vs. 92.3%, P < 0.001; 91.89% vs. 68.60%, P < 0.001; 75.5% vs. 60.60%, P < 0.001; respectively, Table 2). The median OS was 17.4 months for the RT + PD1 group and 11.9 months for the TACE plus sorafenib group (HR: 0.70, 95% CI, 0.38–1.30, P = 0.146; Table 2 and Fig. 3B). There were no significant differences for the median OS in the distribution of the two groups, but a trend toward a more favorable outcome in the RT + PD1 group. Patients in the RT + PD1 group had statistically significant better OS than those in the TACE plus sorafenib group with AFP level ≥ 400 ng/ml, BCLC stage C and MVI (11.8 vs. 9.7 months, P = 0.026; 11.8 vs. 9.7 months, P = 0.031; 11.8 vs. 9.7 months, P = 0.026; respectively, Fig. 5). Although, there had not significant better OS with BCLC stage C and MVI using univariate Cox proportional risk model and R 4.0.5. The effect of the two groups on median OS was consistent across subgroups based on other baseline characteristics (Fig. 4B).

Safety profile
The TRAEs, which occurred in ≥10% of patients, are summarized in Table 3. No deaths were attributed to TRAEs in this study. The TRAEs in the RT + PD1 group show less than in the TACE plus sorafenib group, including increased AST (54.05% vs 92.68%, P < 0.001), increased AST (51.35% vs. 80.49%, P = 0.008), hand-foot skin reaction (HFSR) (0% vs. 53.66%, P < 0.001). Decreased hemoglobin was more frequent in the RT + PD1 group than in the TACE plus sorafenib group (89.19% vs. 68.29%, P = 0.031). There were no differences in regard to other TRAEs such as decreased albumin, decreased white blood...
Increased blood bilirubin and decreased platelet count. Grade 3 or more TRAEs occurred significantly less in patients in the RT + PD1 group than in the TACE plus sorafenib group (29.7% vs. 75.6%, \( P < 0.001 \)). The major grade 3 or more TRAEs were observed significantly milder in the RT + PD1 group than in the TACE plus sorafenib group, including increased aspartate aminotransferase (AST) (5.41% vs. 58.54%, \( P < 0.001 \)), increased alanine aminotransferase (ALT) (5.41% vs. 36.59%, \( P < 0.001 \)) and hand-foot skin reaction (0% vs. 14.63%, \( P = 0.027 \)). The two groups did not differ in terms of other grade 3 or more TRAEs including decreased hemoglobin, decreased albumin, decreased white blood cell, increased blood bilirubin and decreased platelet count.

**Discussion**

Few studies have compared the efficacy and safety of RT + anti-PD1 therapy vs. TACE + sorafenib for treating advanced HCC. In the present real-world study, RT + anti-PD1 therapy was associated with significantly better PFS and ORR, as well as milder, more acceptable TRAEs. Thus, combining anti-PD1 therapy with RT may be an effective, safe treatment for advanced HCC.

Sorafenib is recommended as the first-line treatment for the patients with advance HCC [4], in whom the drug was associated with median OS of 6.5 months, DCR of 35.3%, and ORR of 3.3% in a study of patients in the Asia-Pacific region [31], or 10.4 months, 64%, and 4% in the ORIENT-32 study [29]. We found that combining sorafenib with TACE led to better outcomes, as did using RT + anti-PD1 therapy. Similarly, TACE + sorafenib has been associated with better outcomes than TACE or sorafenib alone in patients with unresectable HCC [6, 8, 9, 32]. In the GIDEON study of patients treated with sorafenib, median OS was 12.7 months among those previously treated with TACE group, 9.2 months among those not previously treated with TACE. The median OS of our patients treated by TACE + sorafenib was 11.9 months, similar to the patients previously treated by
TACE in the GIDEON study [6]. This similarity, despite the much higher proportions of our patients in BCLC stages A or B or with chronic HBV infection, strongly suggests that combining TACE and sorafenib can benefit patients with advanced HCC.

In our real-world study, the PR rate, ORR and DCR were significantly higher in the RT + PD1 group than the TACE + sorafenib group, according to both RECIST 1.1 and mRECIST. In fact, ORR was better in our study (54.05%) than in the IMbrave150 trial (27.3%) [13] or the REFLECT trial (24.1%) [33]. We observed significantly better PFS in patients treated with RT + anti-PD1 than in those treated with TACE + sorafenib. OS at 3, 6, or 9 months was significantly better in the RT + PD1 group than in the TACE + sorafenib group, and the 6-month OS in our RT + PD1 group (91.89%) was better than that in the IMbrave150 trial (84.8%) [13]. Moreover, there was a trend toward longer median OS in the RT + PD1 group than in the TACE + sorafenib group (17.4 months vs. 11.9 months), and the failure of this difference to achieve significance may reflect the significantly shorter median follow-up in the RT + PD1 group (13.4 months vs. 16.6 months). These findings suggest that RT + anti-PD1 and TACE + sorafenib can benefit patients with advanced HCC.

Subgroup analysis revealed that the median PFS in the PD1 + RT group was significantly longer than in the TACE + sorafenib group across subgroups based on age ≥ 53, HBV infection, maximum tumor diameter < 10 cm, MVI, absence of extrahepatic metastasis, BCLC stage C, no prior TACE, prior hepatectomy, or no prior systemic therapy. RT + PD1 was associated with significantly longer OS than TACE + sorafenib among patients with an AFP level ≥ 400 ng/ml, BCLC stage C and MVI. However, the OS difference did not achieve significance among patients with BCLC stage C or MVI, which may be explained by the shorter follow-up time for the PD1 + RT group. Together, these findings may help select patients with advanced HCC who may particularly benefit from combining RT and anti-PD1 or combining TACE and sorafenib therapy.

The spectrum, incidence, and severity of adverse events in the TACE + sorafenib group were consistent with safety profiles in other studies [5, 7–9, 34]. There were fewer total TRAEs and fewer grade 3 or above TRAEs in the RT + PD1 group than in the TACE + sorafenib group, including increased AST, AST and hand-foot skin reaction.

This study had several limitations. Its retrospective design was the main drawback, which may increase the risk of confounding due to differences in adherence or socioeconomic status. Second, the follow-up period was significantly shorter in the RT + PD1 group than in the TACE + sorafenib group, yet it was long enough to evaluate PFS and tumor response, which may be better indicators of efficacy than OS [35]. Third, three types of anti-PD1 drugs were used in this study and they may differ in efficacy, which may have confounded our results. Fourth, we were unable to assess some adverse events such as cardio-toxicity for lack of standard hematological test data.

**Conclusion**

Among patients with advanced HCC, RT + anti-PD1 therapy may be associated with significantly better PFS, PR rate, ORR and DCR than TACE + sorafenib, as well
as better OS among subgroups of patients in BCLC stage C, or with macrovascular invasion or AFP ≥ 400 ng/ml. Adverse events were milder in patients treated with RT + anti-PD1 therapy than in those treated with TACE + sorafenib. Our results, which should be verified in larger studies with longer follow-up, support RT + anti-PD1 therapy as a potential treatment for advanced HCC.

![Fig. 4 Forest plot of PFS A and OS B in subgroups of patients. RT Radiotherapy; PD1 Monoclonal antibody against programmed cell death; TACE Transcatheter arterial chemoembolization; OS Overall survival; PFS Progression-free survival; HBV Hepatitis B; BCLC Barcelona Clinic Liver Cancer; AFP Alpha-fetoprotein](image)

Table 3 Treatment-related adverse events based on CTCAE 5.0

| Adverse events | RT + PD1, N = 37 (%) | TACE + sorafenib, N = 41 (%) | P value |
|----------------|----------------------|------------------------------|---------|
| Increased AST  | Any grade (%) 40(54.05) Grade 3–4 (%) 2(5.41) | Any grade (%) 38(92.68) Grade 3–4 (%) 24(58.54) | <0.001 |
| Increased ALT  | 19(51.35) Grade 3–4 (%) 2(5.41) | 33(80.49) Grade 3–4 (%) 15(36.59) | 0.008 |
| Hand-foot skin reaction | 0(0) | 2(5.41) | <0.001 |
| Decreased hemoglobin | 33(89.19) Grade 3–4 (%) 5(13.51) | 28(68.29) Grade 3–4 (%) 2(4.88) | 0.031 |
| Decreased albumin | 30(81.08) Grade 3–4 (%) 0(0) | 37(90.24) Grade 3–4 (%) 12(2.94) | 0.333 |
| Decreased white blood cell | 28(75.68) Grade 3–4 (%) 3(8.11) | 12(29.27) Grade 3–4 (%) 12(2.94) | <0.001 |
| Increased blood bilirubin | 20(54.05) Grade 3–4 (%) 12(70.6) | 16(39.02) Grade 3–4 (%) 12(2.94) | 0.256 |
| Decreased platelet count | 19(51.35) Grade 3–4 (%) 2(5.41) | 14(34.115) Grade 3–4 (%) 5(12.0) | 0.169 |

Data are N (%)

CTCAE 5.0: The Common Terminology Criteria for Adverse Events of the National Cancer Institute v5.0; RT Radiotherapy; PD1 The monoclonal antibody against programmed cell death 1; TACE Transcatheter arterial chemoembolization; AST Aspartate aminotransferase; ALT Alanine aminotransferase
Abbreviations
TACE: Transcatheter arterial chemoembolization; PFS: Progression-free survival; OS: Overall survival; HCC: Hepatocellular carcinoma; RT: Radiotherapy; anti-PD1: Monoclonal antibody against programmed cell death; TACE: Transcatheter arterial chemoembolization; OS: Overall survival; PFS: Progression-free survival; BCLC-C: Barcelona Clinic Liver Cancer C stage; MVI: Macrovascular invasion; AFP: Alpha-fetoprotein.

Acknowledgements
We wish to thank all patients involved in this study and our colleagues at Guangxi Medical University Cancer Hospital.

Author contributions
XBD conceived the study; all authors participated in the acquisition of the data; LJX and DWX analyzed data; LJX, HST and LXF assessed tumor response; LJX drafted and revised the manuscript. All authors read and approved the final manuscript.

Funding
This study was funded by the Development and Application Project for the Appropriate Technology of Health of Guangxi Province (No. S2019039), the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province (Z20201371), and the Youth Program of Scientific Research Foundation of Guangxi Medical University Cancer Hospital (2021-10).

Availability of data and materials
The data underlying this article will be shared on reasonable request to the corresponding author.

Declarations
Ethics approval and consent to participate
All the procedures were carried out in accordance with the Helsinki Declaration of 1975. This study was approved by the institutional review board of Guangxi Medical University Cancer Hospital (number LW20211104). Patient consent was waived due to the retrospective nature of the study.

Consent for publication
Not applicable.

Competing interests
The authors have no conflict of interest to declare that are relevant to the content of this article.

Author details
1 Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China. 2 School of Public Health, Guangxi Medical University, Nanning 530021, China. 3 Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
2. Zhong JH, Peng NF, You XM, Ma L, Xiang W, Wang YY, Gong WJ, Wu FX, Xiang BD, Li LQ. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: a real-world study. Oncotarget. 2017;8(11):18296–302.
3. Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001;48(1):103–9.
4. Benson AB, D’Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(5):541–65.
5. Chao Y, Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer. 2015;136(6):1458–67.
6. Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladrón de Guevara L, Papandreou C, et al. TACE treatment in patients with Sorafenib-treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON. Radiology. 2016;279(2):630–40.
7. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial...
chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011;29(30):3960–7.
8. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryooy BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013;269(2):603–11.
9. Park JW, Kim YJ, Dae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial. J Hepatol. 2019;70(4):686–91.
10. Liang SX, Zhu XD, Lu H, Pan CY, Li FX, Huang QF, Wang AY, Chen LT, Fu XL, Jiang GL. Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer. 2005;103(10):2181–8.
11. Hong TS, Wo JY, Yeap BY, Ben‑Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, et al. Multi‑institutional phase II study of high‑dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2016;34(5):460–8.
12. Choi SH, Seong J. Strategic application of radiotherapy for hepatocellular carcinoma. Clin Mol Hepatol. 2018;24(2):114–4.
13. Finn RS, Qin S, Ikeda M, Galle PR, Druceux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905.
14. Rao Q, Li M, Xu W, Pang K, Gao X, Wang D, Liu J, Guo W, Zhang Z. Clinical benefits of PD‑1/P‑L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int. 2020;14(5):765–75.
15. Herrera FG, Bourhis J, Coulous G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67(1):65–85.
16. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities in patients with advanced hepatocellular carcinoma: the phase III STAH trial. J Hepatol. 2019;70(4):686–91.
17. Feng RS, Qin S, Ikeda M, Galle PR, Druceux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905.
18. Chiang CL, Chan ACY, Chiu KWH, Kong FS. Combined stereotactic body radiation therapy criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2015;51(17):2043–54.
19. Breslow N. A generalized Kruskal‑ Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika. 1970;57(3):S79–94.
20. Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, et al. Atezolizumab and bevacizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open‑label, parallel‑group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):S71–80.
21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata‑driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
22. Breslow N. A generalized Kruskal‑Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika. 1970;57(3):S79–94.
23. Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, et al. Atezolizumab and bevacizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open‑label, parallel‑group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):S71–80.
24. Chen A‑L, Kang Y‑K, Chen Z, Tsao C‑J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T‑S, et al. Efficacy and safety of sorafenib in patients in the Asia‑Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double‑blind, placebo‑controlled trial. Lancet Oncol. 2009;10(1):25–34.
25. Kudo M, Ushema K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492–501.
26. Kudo M, Finn RS, Qin S, Han K‑H, Ikeda K, Piscaglia F, Baron A, Park J‑W, Han G, Jassiem J, et al. Lenvatinib versus sorafenib in first‑line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non‑inferiority trial. Lancet. 2018;391(10126):1163–73.
27. Cheng A‑L, Kang Y‑K, Chen Z, Tsao C‑J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T‑S, et al. Efficacy and safety of sorafenib in patients in the Asia‑Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double‑blind, placebo‑controlled trial. Lancet Oncol. 2009;10(1):25–34.
28. Kudo M, Finn RS, Qin S, Han K‑H, Ikeda K, Piscaglia F, Baron A, Park J‑W, Han G, Jassiem J, et al. Lenvatinib versus sorafenib in first‑line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non‑inferiority trial. Lancet. 2018;391(10126):1163–73.
29. Llovet JM, Villanueva A, Mannelli M, Bruix J, Reig M, Mazzaferro V, et al. Sorafenib alone versus sorafenib combined with chemoembolization with drug‑eluting beads for hepatocellular carcinoma: US regional analysis of the GIDEON registry. Liver Cancer. 2016;5(1):37–46.